Lysergic Acid Diethylamide (LSD) and Lisuride: Differentiation of Their Neuropharmacological Actions
Francis J. White, James B. Appel
Science April 30, 1982 DOI: 10.1126/science.7071600 via OpenAlex
Summary
AI-generated from the abstractLisuride, a nonhallucinogenic ergot derivative, shares many pharmacological effects with its hallucinogenic counterpart, lysergic acid diethylamide (LSD). Using animals trained to discriminate between the two drugs, researchers found that the LSD cue resembles that of the serotonin agonist quipazine, while the lisuride cue resembles that of the dopamine agonist apomorphine. These findings support the hypothesis that serotonin plays a key role in the hallucinogenic effects of LSD.
Study at a glance
| Characteristics | Animal discrimination study Peer reviewed |
|---|---|
| Population | Animals |
| Topics | LSD Serotonin |
| Keywords | Lisuride Quipazine Hallucinogen Apomorphine |
| Citations | 67 |
| Key finding | The LSD cue is similar to the serotonin agonist quipazine, whereas the lisuride cue is similar to the dopamine agonist apomorphine, supporting serotonin's involvement in LSD's hallucinogenic effects. |
Abstract
The nonhallucinogenic ergot derivative lisuride exerts many pharmacological effects that are similar to those of its hallucinogenic congener, lysergic acid diethylamide (LSD). Animals trained to discriminate between the presence of one drug and the other can be used to differentiate the actions of these compounds on a neuronal level. The discriminative stimulus effect of LSD (the LSD cue) is similar to that of the serotonin agonist quipazine, whereas the lisuride cue is similar to that of the dopamine agonist apomorphine. These data support the hypothesis that serotonin is intricately involved in the hallucinogenic effects of LSD.